{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:25:32Z","timestamp":1787646332159,"version":"build-2736575974"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"abstract":"\n \n Purpose:<\/jats:italic>\n <\/jats:title>\n \n Radionuclide therapy targeting fibroblast activation protein (FAP) offers an effective treatment for tumors with high FAP expression, such as those imaged with\n 68<\/jats:sup>\n Ga-fibroblast activation protein inhibitor (FAPI) and treated with\n 177<\/jats:sup>\n Lu-FAPI. Personalized therapy planning, based on imaging-derived standardized uptake values, pharmacokinetic parameters, and dosimetric modeling, is essential to optimize therapeutic outcomes while minimizing toxicity to healthy tissues.\n <\/jats:p>\n <\/jats:sec>\n \n \n Methods and Results:<\/jats:italic>\n <\/jats:title>\n \n The study develops a comprehensive personalized therapy planning framework integrating\n 68<\/jats:sup>\n Ga-FAPI positron emission tomography (PET), pharmacokinetic modeling, and voxel-based dosimetry for optimized tumor doses and safety in\n 177<\/jats:sup>\n Lu-FAPI radionuclide therapy. A cohort of 26 patients (mean age: 56.3 \u00b1 9.2 years) with stage I\u2013II rectal cancer underwent\n 68<\/jats:sup>\n Ga-FAPI PET\/computed tomography imaging after intravenous injection of\n 68<\/jats:sup>\n Ga-FAPI (150\u2013250 MBq). SUV\n max<\/jats:sub>\n ranged from 8.5 to 12.5, with imaging performed at multiple time points (10, 30, 60, and 120 min) to capture tracer kinetics. Pharmacokinetic modeling was used to estimate uptake rate (K\n 1<\/jats:sub>\n = 0.182 \u00b1 0.036 min\n \u22121<\/jats:sup>\n ), washout rate (k\n 2<\/jats:sub>\n = 0.094 \u00b1 0.021 min\n \u22121<\/jats:sup>\n ), and retention coefficient (k\n 3<\/jats:sub>\n = 0.138 \u00b1 0.028 min\n \u22121<\/jats:sup>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n \n Results:<\/jats:italic>\n <\/jats:title>\n \n Voxel-based dosimetry derived absorbed doses using time\u2013activity curves and radionuclide-specific S-values. Activity scaling was applied to estimate tumor doses with 3\u20137 GBq of\n 177<\/jats:sup>\n Lu-FAPI. With 5\u20137 GBq of\n 177<\/jats:sup>\n Lu-FAPI, 92.3% of patients received tumor doses of at least 20 Gy, ranging from 18.2 to 26.4 Gy. Kidney dosages ranged from 2.2 to 5.0 Gy, whereas liver doses varied from 1.7 to 4.1 Gy. SUV\n max<\/jats:sub>\n showed a high correlation with absorbed dose (\n r<\/jats:italic>\n = 0.88,\n p<\/jats:italic>\n < 0.001).\n <\/jats:p>\n <\/jats:sec>\n \n \n Conclusions:<\/jats:italic>\n <\/jats:title>\n The methodology successfully enhanced tumor dose coverage while ensuring organ safety through activity optimization. This system offers a clinically applicable approach to targeted radionuclide therapy by combining PET imaging, pharmacokinetics, and dosimetry to deliver optimal tumor doses while meeting organ-at-risk constraints.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10849785261479557","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T05:19:11Z","timestamp":1787375951000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic Evaluation of Fibroblast Activation Protein-Targeted Radiopharmaceutical Uptake in Low-Stage Rectal Cancer Tumor Microenvironment"],"prefix":"10.1177","author":[{"given":"XuDong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Affiliated Hospital of North Sichuan Medical College, North Sichuan Medical College, Nanchong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Affiliated Hospital of North Sichuan Medical College, North Sichuan Medical College, Nanchong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuHan","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Affiliated Hospital of North Sichuan Medical College, North Sichuan Medical College, Nanchong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2459-3488","authenticated-orcid":false,"given":"Tong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Affiliated Hospital of North Sichuan Medical College, North Sichuan Medical College, Nanchong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2025.07.008"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.94788"},{"issue":"12","key":"e_1_3_2_4_1","first-page":"967","article-title":"Unveiling the tumor microenvironment through fibroblast activation protein targeting in diagnostic nuclear medicine: A didactic review on biological rationales and key imaging agents","volume":"13","author":"Fouillet J","year":"2024","unstructured":"3.Fouillet J, , Torchio J, , Rubira L, et al. Unveiling the tumor microenvironment through fibroblast activation protein targeting in diagnostic nuclear medicine: A didactic review on biological rationales and key imaging agents. Biology (Basel) 2024;13(12):967.","journal-title":"Biology (Basel)"},{"key":"e_1_3_2_5_1","first-page":"12","article-title":"Targeted radionuclide therapy: A systematic review of advances; challenges; and future directions","author":"Harshith R","year":"2025","unstructured":"4.Harshith R. Targeted radionuclide therapy: A systematic review of advances; challenges; and future directions. Biospecia 2025:12\u201318.","journal-title":"Biospecia"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2022.04.007"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-026-00830-z"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17244019"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/9798898813543125010004"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143418"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06144-0"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14207248"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27165231"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.13833"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.77279"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/s23052599"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/108497802760363187"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020297"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263292"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2018.2505"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267927"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261479557","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10849785261479557","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261479557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:50:57Z","timestamp":1787644257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10849785261479557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":20,"alternative-id":["10.1177\/10849785261479557"],"URL":"https:\/\/doi.org\/10.1177\/10849785261479557","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"10849785261479557"}}